Misplaced Pages

Autologous cultured chondrocytes on porcine collagen membrane (Maci) is a treatment to correct cartilage defects in the knee. It is used to treat symptomatic, full-thickness cartilage defects of the knee with or without bone involvement. Autologous cultured chondrocytes on porcine collagen membrane is an autologous cellularized scaffold product. This treatment is approved by the US Food and Drug Administration (FDA). It is only administered to adults. Healthy cartilage is removed from the person's own knees and a 'scaffold' is created on which the healthy tissue growths. This is an autologous matrix-induced chondrogenesis procedure which prevents tissue rejection complications since the transplanted cartilage comes from the same person.

Autologous cultured chondrocytes on porcine collagen membrane was approved for use in the United States in May 2019.

See also

• Microfracturing
• Knee osteoarthritis
• Knee pain

References

1. ^ "Maci- autologous cultured chondrocytes implant". DailyMed. 23 October 2019. Retrieved 1 April 2020.
2. ^ "Maci (Autologous Cultured Chondrocytes on a Porcine Collagen Membrane)". U.S. Food and Drug Administration (FDA). Retrieved 13 May 2017. This article incorporates text from this source, which is in the public domain.
3. Megan B (December 14, 2016). "FDA Clears Novel Scaffold for Knee Cartilage Repair". Medscape. Retrieved 13 May 2017.

This medical treatment–related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Drugs not assigned an ATC code
• Implants (medicine)
• Orthopedic surgical procedures
• Knee treatments
• Medical treatment stubs